DVAX — Dynavax Technologies Income Statement
0.000.00%
Last trade - 00:00
- $1.34bn
- $841.09m
- $232.28m
- 65
- 23
- 36
- 36
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 35.2 | 46.6 | 439 | 723 | 232 |
Cost of Revenue | |||||
Gross Profit | 15.8 | 32.6 | 266 | 461 | 182 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 170 | 115 | 310 | 439 | 269 |
Operating Profit | -135 | -68.4 | 129 | 284 | -37 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -153 | -75.2 | 77.5 | 294 | -4.37 |
Provision for Income Taxes | |||||
Net Income After Taxes | -153 | -75.2 | 76.7 | 293 | -6.39 |
Net Income Before Extraordinary Items | |||||
Net Income | -153 | -75.2 | 76.7 | 293 | -6.39 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -156 | -75.2 | 72.1 | 296 | -6.39 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2 | -0.792 | 0.588 | 1.97 | -0.035 |